bluebird bio Announces FDA Priority Review Of theBiologics License Application For lovotibeglogene autotemcel (lovo-cel) In Patients With Sickle Cell Disease 12 Years And Older With A History Of Vaso-Occlusive Events
Portfolio Pulse from Bill Haddad
bluebird bio announced that the FDA has granted priority review for its Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) in patients with sickle cell disease aged 12 years and older with a history of vaso-occlusive events.
June 21, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
bluebird bio's stock may see a positive impact as the FDA granted priority review for its BLA for lovo-cel in patients with sickle cell disease.
The FDA granting priority review for bluebird bio's BLA for lovo-cel indicates that the regulatory body sees the potential benefits of the treatment for patients with sickle cell disease. This news may lead to increased investor confidence in the company's pipeline and potential for future revenue growth, resulting in a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100